US appeals court affirms hold on pedigree requirements
This article was originally published in Scrip
A US federal appeals court has affirmed a preliminary injunction blocking implementation of federal drug pedigree requirements. The injunction was granted in late 2006 at the request of secondary wholesalers, who challenged theFDA's decision to begin enforcing pedigree requirements for wholesalers who are not "authorised distributors". The provisions, which are aimed at stemming counterfeiting, would have required non-authorised distributors to provide written documentation of the chain of custody of products. The secondary wholesalers asserted they could not comply because authorised distributors were not required to turn over the necessary documentation to them. The appeals court agreed with the trial judge's ruling that the plaintiffs had demonstrated a likelihood of success on the merits of their claim that the FDA's actions were arbitrary and capricious.
You may also be interested in...
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.